Administration of micronized palmitoylethanolamide (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results
Open-label, no control groupHumansWith transpolydatin
This study tested palmitoylethanolamide together with transpolydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 24 women with suspected endometriosis and severe pelvic pain
- Dose used in the study
- Two tablets a day of PEA 400 mg plus polydatin 40 mg
- Duration
- 90 days, assessed monthly
- What was measured
- VAS for overall pelvic pain, dysmenorrhoea, dyspareunia, dysuria and dyschezia; quality of life; painkiller diary
What the authors reported
Pelvic pain, dysmenorrhoea and dyspareunia fell from baseline. Dysuria and dyschezia did not change significantly. NSAID use fell.
Limits of this study
24 women, no control group, no blinding, endometriosis suspected rather than confirmed. Published in Italian; checked against the English abstract.
Source
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.